DaVita stock kpis
Want to see DVA full AI Analyst Report?
Adjusted Operating Profit by Segment
DaVita reported adjusted operating profit by segment of $562.00M in Q3 2026, down 2.9% from Q2 2026 and up 8.7% year over year. The highest value was $586.00M in Q4 2025.
Reflects the profitability of each segment after adjustments, offering a clearer picture of core earnings and financial health.
Dialysis remains the profit engine, but the story is the sharp inflection in Ancillary Services—moving from steady losses to material, volatile positives—now a meaningful swing factor for enterprise OI. Corporate costs have modestly eased, adding some operating leverage. Management’s Q2 color (phosphate‑binder savings, IKC/International contributions) supports near‑term margin stability, yet revenue‑per‑treatment pressure and ACA mix headwinds mean gains from ancillary and cost saves may be offset, keeping back‑half margin expansion uncertain.
DVA Adjusted Operating Profit by Segment
| Period | Dialysis | Ancillary Services | Corporate | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $544.00M | $44.00M | -$26.00M | $562.00M |
| Q2 2026Jun 30, 2026 | $538.00M | $57.00M | -$16.00M | $579.00M |
| Q1 2026Mar 31, 2026 | $506.00M | $6.00M | -$30.00M | $482.00M |
| Q4 2025Dec 31, 2025 | $556.00M | $62.00M | -$32.00M | $586.00M |
| Q3 2025Sep 30, 2025 | $542.00M | $1.00M | -$26.00M | $517.00M |
| Q2 2025Jun 30, 2025 | $536.00M | $57.00M | -$42.00M | $551.00M |
| Q1 2025Mar 31, 2025 | $476.00M | -$3.00M | -$34.00M | $439.00M |
| Q4 2024Dec 31, 2024 | $482.00M | $25.00M | -$29.00M | $478.00M |
| Q3 2024Sep 30, 2024 | $549.00M | $14.00M | -$29.00M | $534.00M |
| Q2 2024Jun 30, 2024 | $550.00M | -$19.00M | -$25.00M | $506.00M |
| Q1 2024Mar 31, 2024 | $505.00M | -$12.00M | -$30.00M | $463.00M |
| Q4 2023Dec 31, 2023 | $476.00M | -$27.00M | -$24.00M | $425.00M |
| Q3 2023Sep 30, 2023 | $537.00M | $28.00M | -$41.00M | $524.00M |
| Q2 2023Jun 30, 2023 | $487.00M | -$22.00M | -$33.00M | $432.00M |
| Q1 2023Mar 31, 2023 | $400.00M | -$24.00M | -$24.00M | $352.00M |
| Q4 2022Dec 31, 2022 | $398.00M | -$33.00M | -$38.00M | $327.00M |
| Q3 2022Sep 30, 2022 | $391.00M | -$15.00M | -$24.00M | $352.00M |
| Q2 2022Jun 30, 2022 | $473.00M | -$9.00M | -$31.00M | $433.00M |
| Q1 2022Mar 31, 2022 | $406.00M | -$32.00M | -$36.00M | $338.00M |
| Q4 2021Dec 31, 2021 | $451.00M | -$29.00M | -$34.00M | $388.00M |
| Q3 2021Sep 30, 2021 | $510.00M | -$7.00M | -$28.00M | $475.00M |
| Q2 2021Jun 30, 2021 | $534.00M | -$18.00M | -$25.00M | $491.00M |
| Q1 2021Mar 31, 2021 | $480.00M | -$12.00M | -$25.00M | $443.00M |
| Q4 2020Dec 31, 2020 | $432.00M | -$27.00M | -$24.00M | $381.00M |
| Q3 2020Sep 30, 2020 | $471.00M | -$7.00M | -$26.00M | $438.00M |
| Q2 2020Jun 30, 2020 | $523.00M | -$23.00M | -$38.00M | $462.00M |
| Q1 2020Mar 31, 2020 | $492.00M | -$3.00M | -$24.00M | $465.00M |

